Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Argus Analyst Says

Gilead Sciences (NASDAQ:GILD) had its price objective boosted by Argus from $135.00 to $165.00 in a report released on Thursday,MarketScreener reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Argus’ price objective indicates a potential upside of 8.98% from the stock’s previous close.

A number of other equities research analysts have also weighed in on GILD. Scotiabank lifted their target price on shares of Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research note on Wednesday, February 11th. HSBC increased their target price on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research note on Wednesday, December 10th. Wells Fargo & Company increased their price target on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Wolfe Research lifted their price objective on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Finally, Bank of America set a $162.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, February 11th. Twenty-three analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $155.44.

Gilead Sciences Stock Up 0.2%

Shares of NASDAQ GILD opened at $151.40 on Thursday. The stock has a market capitalization of $187.84 billion, a P/E ratio of 22.36, a PEG ratio of 2.01 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31. Gilead Sciences has a one year low of $93.37 and a one year high of $157.29. The firm’s 50 day simple moving average is $133.47 and its two-hundred day simple moving average is $123.63.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the prior year, the firm posted $1.90 earnings per share. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts expect that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director owned 8,920 shares in the company, valued at $1,101,620. The trade was a 35.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total value of $463,290.00. Following the completion of the sale, the chief financial officer owned 167,779 shares in the company, valued at $25,910,110.97. This represents a 1.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 319,891 shares of company stock valued at $45,091,556. 0.27% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GILD. Sunbelt Securities Inc. raised its holdings in Gilead Sciences by 1.9% during the 4th quarter. Sunbelt Securities Inc. now owns 11,508 shares of the biopharmaceutical company’s stock valued at $1,412,000 after buying an additional 216 shares during the period. Cambient Family Office LLC purchased a new stake in Gilead Sciences in the 4th quarter valued at about $1,122,000. Mcguire Capital Advisors Inc. bought a new position in Gilead Sciences in the fourth quarter worth approximately $43,000. Hamilton Wealth LLC grew its position in shares of Gilead Sciences by 6.1% during the 4th quarter. Hamilton Wealth LLC now owns 38,367 shares of the biopharmaceutical company’s stock worth $4,709,000 after buying an additional 2,208 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. grew its holdings in Gilead Sciences by 13.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 302,669 shares of the biopharmaceutical company’s stock worth $37,150,000 after acquiring an additional 35,769 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 earnings beat and firm guidance: Gilead reported $1.86 EPS vs. $1.83 est. and $7.93B revenue (above estimates) and set FY‑2026 EPS guidance of $8.45–$8.85 — a catalyst for re-rating. Analyst Reactions Post‑Earnings
• Positive Sentiment: Argus raised its price target to $165 and kept a Buy rating, adding analyst-driven upside (~mid-single digits vs. current levels). Argus PT Raise
• Positive Sentiment: Mizuho lifted its target to $170 and kept an Outperform rating, supporting a higher consensus valuation and momentum for buy‑side flows. Mizuho PT Raise
• Neutral Sentiment: Barclays initiated coverage with an Equal‑Weight rating and $155 target — neither a strong buy nor a sell signal, but it provides fresh institutional coverage. Barclays Coverage
• Neutral Sentiment: Broader analyst and media coverage (Zacks, Yahoo, Benzinga retrospectives) is keeping GILD in focus for retail/institutional investors; these pieces inform positioning but are mixed in directional impact. Zacks Coverage
• Neutral Sentiment: Short‑interest data in the feed looks anomalous/zeroed out and provides no clear sell pressure signal at present (data likely noisy).
• Negative Sentiment: Insider selling: CFO Andrew Dickinson sold 3,000 shares (~$154.43 avg price) — a small amount but negative for sentiment when combined with other insider moves. CFO Form 4
• Negative Sentiment: Material insider sale: Johanna Mercier sold 28,000 shares (~$154.44 avg), an ~18.9% reduction in her holding — a larger ticket that can weigh on investor confidence. Mercier Form 4
• Negative Sentiment: “Time to take profits” / rating downgrade commentary is circulating, which can trigger short‑term selling from momentum traders. Seeking Alpha Take‑Profits Piece

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.